/images/ppid_59c68470-image-176457502911996308.webp)
/images/ppid_a911dc6a-image-176432553085145357.webp)
What is the story about?
Shares of Sun Pharmaceutical Industries Ltd. declined on Monday, December 1, after the company introduced its global innovative drug Ilumya (Tildrakizumab) in India for the treatment of moderate-to-severe plaque psoriasis.
The drug is a novel biological treatment, has been endorsed widely by dermatologists in the US and globally for several years as an effective and safe treatment of moderate to severe plaque psoriasis, the company said in an exchange filing.
The company's managing director, Kirti Ganorkar, said Ilumya is already available in 35 countries and has consistently demonstrated significant and long-lasting skin clearance, beginning soon after irritation and sustained over the years.
Sun Pharma's clinical study in India included 15 patients of moderate-to-severe plaque psoriasis. Patients received three subcutaneous injections of Tildrakizumab over 16 weeks and were followed for a period of 28 weeks.
A 75% skin clearance as seen in 62.3%, 83.3%, and 93.9% patients, respectively, in weeks 12, 16 and 28, the company said. A 90% skin clearance was seen in 26.3%, 50% and 78.1% patients, respectively, at Week 12, 16 and 28, it added. Significant improvements were also observed on additional efficacy endpoints such as dermatology life quality index (DLQI) score, the company said.
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis, Sun Pharma said.
Patients living with moderate-to-severe plaque psoriasis need therapies they can use over long periods of time without loss of efficacy, and data show that Ilumya is a sustainable choice for patients over the long term, it added.
Shares of Sun Pharma were down 1.1% at ₹1,8107 apiece around 12.55 pm on Monday. The stock has declined 4.2% this year, so far.
Also Read: Ashok Leyland November auto sales above Street estimates, rise 29% from last year
The drug is a novel biological treatment, has been endorsed widely by dermatologists in the US and globally for several years as an effective and safe treatment of moderate to severe plaque psoriasis, the company said in an exchange filing.
The company's managing director, Kirti Ganorkar, said Ilumya is already available in 35 countries and has consistently demonstrated significant and long-lasting skin clearance, beginning soon after irritation and sustained over the years.
Sun Pharma's clinical study in India included 15 patients of moderate-to-severe plaque psoriasis. Patients received three subcutaneous injections of Tildrakizumab over 16 weeks and were followed for a period of 28 weeks.
A 75% skin clearance as seen in 62.3%, 83.3%, and 93.9% patients, respectively, in weeks 12, 16 and 28, the company said. A 90% skin clearance was seen in 26.3%, 50% and 78.1% patients, respectively, at Week 12, 16 and 28, it added. Significant improvements were also observed on additional efficacy endpoints such as dermatology life quality index (DLQI) score, the company said.
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis, Sun Pharma said.
Patients living with moderate-to-severe plaque psoriasis need therapies they can use over long periods of time without loss of efficacy, and data show that Ilumya is a sustainable choice for patients over the long term, it added.
Shares of Sun Pharma were down 1.1% at ₹1,8107 apiece around 12.55 pm on Monday. The stock has declined 4.2% this year, so far.
Also Read: Ashok Leyland November auto sales above Street estimates, rise 29% from last year
/images/ppid_a911dc6a-image-176439386239667346.webp)
